{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:12:22Z","timestamp":1784304742503,"version":"3.55.0"},"reference-count":41,"publisher":"Becaris Publishing Limited","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            We compared outcomes from a single-arm study of tisagenlecleucel with standard of care (SOC) regimens in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia (ALL).\n            <jats:bold>Methods:<\/jats:bold>\n            The analysis included one tisagenlecleucel study, one blinatumomab study, one clofarabine monotherapy study, three studies of clofarabine combination regimens\u00a0and two studies of other salvage chemotherapy. Matching-adjusted indirect comparison analyses were conducted.\n            <jats:bold>Results:<\/jats:bold>\n            After adjusting for baseline characteristics, tisagenlecleucel was associated with significantly prolonged overall survival compared with blinatumomab (hazard ratio [95% CI], 0.32 [0.16\u20130.64]); clofarabine monotherapy (0.24 [0.13\u20130.42]); clofarabine combination regimens (0.26 [0.15\u20130.45]); two salvage therapies (0.15 [0.09\u20130.25] and 0.27 [0.15\u20130.49]).\n            <jats:bold>Conclusion:<\/jats:bold>\n            The analysis demonstrated tisagenlecleucel was associated with substantially greater survival benefit versus all SOC regimens.\n          <\/jats:p>","DOI":"10.2217\/cer-2020-0069","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T19:56:51Z","timestamp":1593547011000},"page":"849-860","source":"Crossref","is-referenced-by-count":7,"title":["Tisagenlecleucel versus historical standard therapies for pediatric relapsed\/refractory acute lymphoblastic leukemia"],"prefix":"10.57264","volume":"9","author":[{"given":"Qiufei","family":"Ma","sequence":"first","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Evidera, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber L","family":"Martin","sequence":"additional","affiliation":[{"name":"Evidera, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Chassot","family":"Agostinho","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_4_2_2","unstructured":"Incidence of Childhood Leukaemia: Fact Sheet 4.1 (2019). www.euro.who.int\/__data\/assets\/pdf_file\/0005\/97016\/4.1.-Incidence-of-childhood-leukaemia-EDITED_layouted.pdf"},{"issue":"36","key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"950","DOI":"10.15585\/mmwr.mm6636a3","article-title":"Rates and trends of pediatric acute lymphoblastic leukemia \u2013 United States, 2001\u20132014","volume":"66","author":"Siegel DA","year":"2017","unstructured":"Siegel DA , Henley SJ , Li J , Pollack LA , Van Dyne EA , White A . Rates and trends of pediatric acute lymphoblastic leukemia \u2013 United States, 2001\u20132014. MMWR Morb. Mortal. Wkly Rep. 66(36), 950\u2013954 (2017).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"14","key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","article-title":"How I treat relapsed childhood acute lymphoblastic leukemia","volume":"120","author":"Locatelli F","year":"2012","unstructured":"Locatelli F , Schrappe M , Bernardo ME , Rutella S . How I treat relapsed childhood acute lymphoblastic leukemia. Blood 120(14), 2807\u20132816 (2012).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2010.09.020","article-title":"Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group","volume":"47","author":"Von Stackelberg A","year":"2011","unstructured":"Von Stackelberg A , Volzke E , Kuhl JS Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group. Eur. J. Cancer 47(1), 90\u201397 (2011).","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","article-title":"Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study","volume":"28","author":"Ko RH","year":"2010","unstructured":"Ko RH , Ji L , Barnette P Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J. Clin. Oncol. 28(4), 648\u2013654 (2010).","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen G","year":"2010","unstructured":"Tallen G , Ratei R , Mann G Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J. Clin. Oncol. 28(14), 2339\u20132347 (2010).","journal-title":"J. Clin. Oncol."},{"issue":"9757","key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial","volume":"376","author":"Parker C","year":"2010","unstructured":"Parker C , Waters R , Leighton C Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 376(9757), 2009\u20132017 (2010).","journal-title":"Lancet"},{"issue":"12","key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"22","author":"Nguyen K","year":"2008","unstructured":"Nguyen K , Devidas M , Cheng SC Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 22(12), 2142\u20132150 (2008).","journal-title":"Leukemia"},{"issue":"15","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"10008","DOI":"10.1200\/JCO.2019.37.15_suppl.10008","article-title":"Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) study [abstract]","volume":"37","author":"Rheingold SR","year":"2019","unstructured":"Rheingold SR , Ji L , Xu X Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) study [abstract]. J. Clin. Oncol. 37(Suppl. 15), 10008 (2019).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_4_11_2","article-title":"CLOLAR","author":"Genzyme Corporation","year":"2016","unstructured":"Genzyme Corporation. CLOLAR. Clofarabine (2016). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021673s025lbl.pdf","journal-title":"Clofarabine"},{"key":"e_1_3_4_12_2","unstructured":"European Medicines Agency. EVOLTRA (clofarabine) EPAR Summary for the Public (2015). www.ema.europa.eu\/en\/documents\/overview\/evoltra-epar-summary-public_en.pdf"},{"issue":"12","key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"24","author":"Jeha S","year":"2006","unstructured":"Jeha S , Gaynon PS , Razzouk BI Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J. Clin. Oncol. 24(12), 1917\u20131923 (2006).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_4_14_2","unstructured":"A Phase II open-label study of clofarabine in paediatric patients with refractory\/relapsed acute lymphoblastic leukaemia (2004). www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-001853-27\/results"},{"key":"e_1_3_4_15_2","article-title":"BLINCYTO","author":"Amgen Inc","year":"2018","unstructured":"Amgen Inc. BLINCYTO. Blinatumomab (2018). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125557s013lbl.pdf","journal-title":"Blinatumomab"},{"key":"e_1_3_4_16_2","unstructured":"Amgen receives FDA breakthrough therapy designation for investigational BiTE \u00ae Antibody blinatumomab in acute lymphoblastic leukemia (2014). http:\/\/investors.amgen.com\/phoenix.zhtml?c=61656&p=irol-newsArticle&ID=1944069"},{"issue":"8","key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/CJI.0b013e318156750c","article-title":"Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class","volume":"30","author":"Brischwein K","year":"2007","unstructured":"Brischwein K , Parr L , Pflanz S Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J. Immunother. 30(8), 798\u2013807 (2007).","journal-title":"J. Immunother."},{"issue":"36","key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"Von Stackelberg A","year":"2016","unstructured":"Von Stackelberg A , Locatelli F , Zugmaier G Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J. Clin. Oncol. 34(36), 4381\u20134389 (2016).","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian H","year":"2017","unstructured":"Kantarjian H , Stein A , Gokbuget N Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376(9), 836\u2013847 (2017).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_4_20_2","article-title":"Kymriah","author":"Novartis Pharmaceuticals Corporation","year":"2018","unstructured":"Novartis Pharmaceuticals Corporation. Kymriah. Tisagenlecleucel (2018). www.novartis.com\/news\/media-releases\/kymriah-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma","journal-title":"Tisagenlecleucel"},{"key":"e_1_3_4_21_2","article-title":"Kymriah","author":"Novartis Europharm Limited","year":"2018","unstructured":"Novartis Europharm Limited. Kymriah. Tisagenlecleucel (2018). www.novartis.com\/news\/media-releases\/novartis-receives-european-commission-approval-its-car-t-cell-therapy-kymriah-tisagenlecleucel","journal-title":"Tisagenlecleucel"},{"key":"e_1_3_4_22_2","unstructured":"Novartis Pharmaceuticals Canada Inc. Kymriah (tisagenlecleucel). Health Canada Product Monograph (2018). www.newswire.ca\/news-releases\/novartis-receives-health-canada-approval-of-its-car-t-cell-therapy-kymriah-tisagenlecleuceli-692581041.html"},{"key":"e_1_3_4_23_2","unstructured":"KymriahTM Zellsuspension zur Infusion (Tisagenlecleucelum) (2018). www.swissmedic.ch\/swissmedic\/de\/home\/humanarzneimittel\/authorisations\/new-medicines\/kymriahtm_zellsuspensionzurinfusiontisagenlecleucelum.html"},{"key":"e_1_3_4_24_2","unstructured":"Novartis Pharmaceuticals Australia Pty Ltd. Kymriah (tisagenlecleucel). Australian Prescribing Information (2018). www.nps.org.au\/assets\/p30-New-drug-2-Tisagenlecleucel-v2.pdf"},{"issue":"5","key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude SL","year":"2018","unstructured":"Maude SL , Laetsch TW , Buechner J Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378(5), 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S1470-2045(19)30493-0","article-title":"Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial","volume":"20","author":"Laetsch TW","year":"2019","unstructured":"Laetsch TW , Myers GD , Baruchel A Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncol. 20(12), 1710\u20131718 (2019).","journal-title":"Lancet Oncol."},{"issue":"6","key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch JE","year":"2012","unstructured":"Signorovitch JE , Sikirica V , Erder MH Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15(6), 940\u2013947 (2012).","journal-title":"Value Health"},{"key":"e_1_3_4_28_2","unstructured":"NICE DSU Technical Support Document 18: Methods for Population-Adjusted Indirect Comparisons in Submissions to NICE (2017). http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2017\/05\/Population-adjustment-TSD-FINAL.pdf"},{"issue":"3","key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.jval.2016.03.1723","article-title":"Matching adjusted indirect comparisons to assess comparative effectiveness of therapies: usage in scientific literature and health technology appraisals","volume":"19","author":"Thom H","year":"2016","unstructured":"Thom H , Jugl SM , Palaka E , Jawla S . Matching adjusted indirect comparisons to assess comparative effectiveness of therapies: usage in scientific literature and health technology appraisals. Value Health 19(3), A1\u2013A318 (2016).","journal-title":"Value Health"},{"key":"e_1_3_4_30_2","unstructured":"Engauge Digitizer Software (2018). http:\/\/markummitchell.github.io\/engauge-digitizer"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves","volume":"12","author":"Guyot P","year":"2012","unstructured":"Guyot P , Ades AE , Ouwens MJ , Welton NJ . Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves. BMC Med. Res. Methodol. 12, 9 (2012).","journal-title":"BMC Med. Res. Methodol."},{"issue":"22","key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V128.22.2801.2801","article-title":"Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed\/refractory acute lymphoblastic leukemia: results of an interim analysis","volume":"128","author":"Maude SL","year":"2016","unstructured":"Maude SL , Pulsipher MA , Boyer MW Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed\/refractory acute lymphoblastic leukemia: results of an interim analysis. Blood 128(22), 2801 (2016).","journal-title":"Blood"},{"issue":"15","key":"e_1_3_4_33_2","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL","volume":"34","author":"Maude SL","year":"2016","unstructured":"Maude SL , Teachey DT , Rheingold SR Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL. J. Clin. Oncol. 34(Suppl.15), (2016). https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2016.34.15_suppl.3011","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude SL","year":"2014","unstructured":"Maude SL , Frey N , Shaw PA Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371(16), 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2018-99-112599","article-title":"Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia","volume":"132","author":"Grupp SA","year":"2018","unstructured":"Grupp SA , Maude SL , Rives S Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia. Blood 132(Suppl. 1), 895 (2018).","journal-title":"Blood"},{"issue":"12","key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/leu.2009.185","article-title":"A multi-center Phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia","volume":"23","author":"Hijiya N","year":"2009","unstructured":"Hijiya N , Gaynon P , Barry E A multi-center Phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 23(12), 2259\u20132264 (2009).","journal-title":"Leukemia"},{"issue":"4","key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2141.2011.08752.x","article-title":"Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia","volume":"154","author":"O'Connor D","year":"2011","unstructured":"O'Connor D , Sibson K , Caswell M Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. Br. J. Haematol. 154(4), 482\u2013485 (2011).","journal-title":"Br. J. Haematol."},{"issue":"1","key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"10530","DOI":"10.1200\/JCO.2017.35.15_suppl.10530","article-title":"Blinatumomab use in pediatric patients (pts) with relapsed\/refractory B-precursor acute lymphoblastic leukemia (r\/r ALL) from an open-label, multicenter, expanded access study","volume":"35","author":"Locatelli F","year":"2017","unstructured":"Locatelli F , Zugmaier G , Vora A Blinatumomab use in pediatric patients (pts) with relapsed\/refractory B-precursor acute lymphoblastic leukemia (r\/r ALL) from an open-label, multicenter, expanded access study. J. Clin. Oncol. 35(1 Suppl. 15), 10530 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1182\/blood-2011-08-374710","article-title":"Phase II trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"118","author":"Hijiya N","year":"2011","unstructured":"Hijiya N , Thomson B , Isakoff MS Phase II trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 118(23), 6043\u20136049 (2011).","journal-title":"Blood"},{"issue":"3","key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2141.2009.07882.x","article-title":"Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory\/multiple relapsed acute lymphoblastic leukaemia","volume":"147","author":"Locatelli F","year":"2009","unstructured":"Locatelli F , Testi AM , Bernardo ME Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory\/multiple relapsed acute lymphoblastic leukaemia. Br. J. Haematol. 147(3), 371\u2013378 (2009).","journal-title":"Br. J. Haematol."},{"issue":"9","key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3109\/10428194.2012.663915","article-title":"Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients","volume":"53","author":"Miano M","year":"2012","unstructured":"Miano M , Pistorio A , Putti MC Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. Leukemia Lymphoma 53(9), 1693\u20131698 (2012).","journal-title":"Leukemia Lymphoma"},{"issue":"1","key":"e_1_3_4_42_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/bjh.14965","article-title":"Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003\/2007 trial","volume":"180","author":"Kuhlen M","year":"2018","unstructured":"Kuhlen M , Willasch AM , Dalle JH Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003\/2007 trial. Br. J. Haematol. 180(1), 82\u201389 (2018).","journal-title":"Br. J. Haematol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2020-0069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:56:37Z","timestamp":1679230597000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2020-0069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.2217\/cer-2020-0069"],"URL":"https:\/\/doi.org\/10.2217\/cer-2020-0069","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}